Skip to main navigation Skip to search Skip to main content

A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer

  • Matthew G. Fury
  • , Eric Sherman
  • , Donna Lisa
  • , Neeraj Agarwal
  • , Kenneth Algazy
  • , Bruce Brockstein
  • , Corey Langer
  • , Dean Lim
  • , Ranee Mehra
  • , Sandeep K. Rajan
  • , Susan Korte
  • , Brynna Lipson
  • , Furhan Yunus
  • , Tawee Tanvetyanon
  • , Stephanie Smith-Marrone
  • , Kenneth Ng
  • , Han Xiao
  • , Sofia Haque
  • , David G. Pfister

Research output: Contribution to journal › Article › peer-review

20   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology